MYX Stock Overview A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Mayne Pharma Group Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Mayne Pharma Group Historical stock prices Current Share Price AU$4.72 52 Week High AU$7.47 52 Week Low AU$3.75 Beta 1.25 1 Month Change 10.80% 3 Month Change 3.51% 1 Year Change -24.96% 3 Year Change -17.19% 5 Year Change -48.97% Change since IPO -71.82%
Recent News & Updates
New major risk - Financial position Aug 23
Full year 2024 earnings released: AU$2.12 loss per share (vs AU$3.86 loss in FY 2023) Aug 23
No longer forecast to breakeven May 18
New minor risk - Profitability May 17
First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023) Feb 28
Forecast to breakeven in 2026 Feb 27 See more updates
New major risk - Financial position Aug 23
Full year 2024 earnings released: AU$2.12 loss per share (vs AU$3.86 loss in FY 2023) Aug 23
No longer forecast to breakeven May 18
New minor risk - Profitability May 17
First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023) Feb 28
Forecast to breakeven in 2026 Feb 27 Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024
Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024 Feb 12
High number of new directors Dec 07
Mayne Pharma Group Limited Approves Election of Anne Lockwood Nov 30
Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023 Oct 27
Independent Non-Executive Director recently bought AU$69k worth of stock Oct 26
Full year 2023 earnings released: AU$3.86 loss per share (vs AU$3.20 loss in FY 2022) Sep 01
New minor risk - Financial data availability Aug 30
Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023 Aug 24 Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023 Jul 27
Independent Non-Executive Chairman recently bought AU$74k worth of stock Mar 28
First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022) Mar 01 Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023
Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring Jan 14
Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD). Dec 05
High number of new directors Nov 16
High number of new directors Nov 02
Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023 Oct 29 Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million. Oct 05
Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022
Mayne Pharma Group Limited Announces Management Changes Aug 31
Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.13 loss in FY 2021) Aug 27
Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited Aug 19
FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette Aug 08
Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia Jul 26
Mayne Pharma Group Limited Announces CFO Changes Jul 22
Forecast breakeven date pushed back to 2024 Mar 01
First half 2022 earnings: EPS in line with expectations, revenues disappoint Feb 28
Mayne Pharma Expands U.S Dermatology Portfolio Feb 10
Insufficient new directors Dec 06
Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive Nov 29
High number of new directors Oct 31
Independent Non Executive Director Bruce Mathieson has left the company Oct 07
Independent Chairman Roger Corbett has left the company Oct 07
Independent Chairman Roger Corbett has left the company Oct 07
U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque Psoriasis Sep 24
Forecast to breakeven in 2023 Sep 23
Independent Non-Executive Director recently bought AU$137k worth of stock Sep 04
Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020) Aug 29
Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published May 27
Mayne Pharma Announces New Data Showing Treatment with Nextstellis® Investigational Combined Oral Contraceptive (Coc) Containing Drospirenone (Drsp) and Estetrol Mar 07
Mayne Pharma Group Limited Launches Another Generic Oral Contraceptive Mar 05
Revenue beats expectations Feb 26
First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.012 loss in 1H 2020) Feb 25 Mayne Pharma Group Limited to Report Fiscal Year 2021 Results on Aug 27, 2021
New 90-day low: AU$0.32 Feb 09
Mayne Pharma Group Limited Launches MICROGESTIN 24 FE Tablets in the United States Jan 08
New 90-day low: AU$0.32 Oct 28
New 90-day low: AU$0.32 Oct 07
Mayne Pharma Group Limited Provides Update on Women's Health Pipeline Oct 06
Mayne Pharma Group Limited Appoints Peter Paltoglou as Chief Financial Officer Sep 29
New 90-day low - AU$0.33 Sep 09
New 90-day low - AU$0.34 Aug 21
Full year earnings released Aug 21
Mayne Pharma Group Limited to Report Fiscal Year 2020 Results on Aug 21, 2020 Aug 07 Mayne Pharma Group Limited(ASX:MYX) dropped from S&P/ASX 200 Index Jun 22
Shareholder Returns MYX AU Pharmaceuticals AU Market 7D -4.3% -4.9% -2.7% 1Y -25.0% -9.3% 6.5%
See full shareholder returns
Return vs Market: MYX underperformed the Australian Market which returned 6.5% over the past year.
Price Volatility Is MYX's price volatile compared to industry and market? MYX volatility MYX Average Weekly Movement 8.0% Pharmaceuticals Industry Average Movement 10.3% Market Average Movement 8.0% 10% most volatile stocks in AU Market 16.8% 10% least volatile stocks in AU Market 3.1%
Stable Share Price: MYX has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: MYX's weekly volatility (8%) has been stable over the past year.
About the Company Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through three segments: Women’s Health, Dermatology, and International. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.
Show more Mayne Pharma Group Limited Fundamentals Summary How do Mayne Pharma Group's earnings and revenue compare to its market cap? MYX fundamental statistics Market cap AU$385.45m Earnings (TTM ) -AU$168.62m Revenue (TTM ) AU$388.40m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) MYX income statement (TTM ) Revenue AU$388.40m Cost of Revenue AU$169.62m Gross Profit AU$218.78m Other Expenses AU$387.39m Earnings -AU$168.62m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -2.08 Gross Margin 56.33% Net Profit Margin -43.41% Debt/Equity Ratio 7.0%
How did MYX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 12:34 End of Day Share Price 2024/12/20 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Mayne Pharma Group Limited is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Russell Wright APP Securities Pty Ltd. Russell Wright Barclay Pearce Capital Pty Limited John Hester Bell Potter
Show 8 more analysts 
